BA
PCVX icon

Bridgewater Associates’s Vaxcyte PCVX Stock Holding History

Bridgewater Associates’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.92M Buy
50,217
+37,314
+289% +$2.03M 0.01% 602
2026
Q1 		$750K Buy
+12,903
New +$700K ﹤0.01% 832
2025
Q4 		– Sell
-11,855
Closed -$427K – 1155
2025
Q3 		$427K Buy
+11,855
New +$393K ﹤0.01% 942

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bridgewater Associates's PCVX Position: Q2 2026 in Review

Bridgewater Associates increased its Vaxcyte (PCVX) stake by 289% in Q2 2026, buying an estimated $2.03M and bringing the position to 50,217 shares worth $2.92M. The position accounts for 0.01% of the portfolio, ranked #602.

Bridgewater Associates first reported a position in PCVX in Q3 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Bridgewater Associates held 50,217 shares of Vaxcyte worth $2.92M as of Q2 2026.
  • Bridgewater Associates bought 37,314 Vaxcyte shares in Q2 2026, an estimated $2.03M.
  • Vaxcyte made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #602 holding.
  • Bridgewater Associates first reported a position in Vaxcyte in Q3 2025 and has held it in 3 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.